Articles tagged with: Aplidin
News»
A recent paper published in Lancet Oncology examines drugs that target biological mechanisms in multiple myeloma. This article is the last of three articles discussing new drugs for myeloma treatment.
Cells have correction mechanisms that prevent deleterious proteins from aggregating. Blocking either of these systems leads to an accumulation of toxins proteins in the cell and results in cell death.
Heat-shock Protein Inhibitors
One system that responds to misfolded proteins is heat-shock proteins (HSP). Among their other functions, these proteins stabilize survival signaling proteins that are overexpressed in multiple myeloma.
By using …
Resources, Treatments Under Development»
| Brand Name: | Aplidin |
| Generic Name: | plitidepsin |
| Code Name: | |
| Company: | PharmaMar, SA |
| FDA Clinical Phase: | 3 |
Description:
Aplidin is derived from a compound found in tunicates which shows promise in shrinking tumors.